Best World takes up 12.5% stake in A*STAR biotech start-up for $5.6 mil

Best World takes up 12.5% stake in A*STAR biotech start-up for $5.6 mil

Michelle Zhu
14/01/19, 07:34 am

SINGAPORE (Jan 14): Best World has agreed to acquire a 15% stake in Celligenics, a biomedical A*STAR spin-off start-up, in two investment phases.  

The first phase will see Best World subscribe for 12.5% of Celligenics shares for $5.625 million, which will be funded by the group’s internal resources.

The second phase will commence 18 months after the first is completed.

It will allow Best World or its designated wholly-owned subsidiary to exercise its right to subscribe for new shares in Cellgenics such that its shareholding in the company is raised to 15% on a fully-diluted basis, and possibly involve subsequent funding to Celligenics should the business scale up in future.  

Best World estimates Celligenics’ issued and paid up share capital to stand at $805,000, comprising 805,000 shares as at Jan 14, while its net liabilities are approximately $349,000 as at end-2017.

In a Monday filing, Best World says it believes its investment in Celligenics is synergistic with its current business in the group’s health & wellness industry.  

This is because the group intends to collaborate with Celligenics to develop “the next generation of cutting edge stem cell-based products” focused on the healthcare and wellness industry categories.

Celligenics may also leverage on Best World’s regional markets and sales network as well as management resources to achieve greater operational efficiency and gain immediate market access, adds the group.

Best World’s executive director and COO, Huang Ban Chin, currently holds a 17% equity interest in Celligenics.

Shares in the group closed 2 cents lower at $2.64 on Friday. 

Ex-remisier Ng denies being coached; RHB trader Alex Chew admits to telling the whole truth only in third statement

SINGAPORE (Apr 23): In Day Six of the trial of John Soh Chee Wen, the defence wrapped up their cross examination of the prosecution’s first witness, former OCBC Securities remisier Ng Kit Kiat. Ng had on Monday admitted to having performed trades without third-party authorisation. The trades performed without third-party authorisation included those based on orders given by a certain Ang Cheau Hoon Alice and Kent Eng Peng Huat, both of whom are remisiers at UOB Kay Hian, for accounts held by Ang's husband Poh Sian Hong as well as Eng's wife Yew Yong Mei. When asked by Soh’s defenc....

Singapore's pre-election cabinet change sets Heng up for top job

(Apr 23): Singapore’s Finance Minister Heng Swee Keat was promoted to deputy prime minister on Tuesday, a move that further positions him to succeed Prime Minister Lee Hsien Loong. Heng will become Lee’s deputy on May 1 while retaining the finance post, the prime minister’s office said in an emailed statement. He will also continue chairing the Future Economy Council and National Research Foundation. The sole cabinet promotion bolsters the odds that 57-year-old Heng will be the ruling People’s Action Party’s choice for prime minister after the general elections, which may come ....

OUE dumps stake in Nuvest Capital with no profit or loss

SINGAPORE (Apr 22): OUE announced it had sold its 33% stake in Nuvest Capital for US$1 million ($1.36 million). The buyer was Aje Kumar Saigal who owns the other 67% of Nuvest Capital. OUE acquired its 33% stake in Nuvest Capital in 2015 for US$1 million, so it has neither made a gain nor a loss. But in 2014, OUE invested US$200 million in Nuvest Real Return Fund which is managed by Nuvest Capital. Last Nov, OUE’s executive chairman had told analysts that the company plans to redeem the fund soon as it had not been profitable. In its FY2014 annual report, OUE's investment in t....